A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults (NCT07618845) | Clinical Trial Compass
Not Yet RecruitingPhase 1
A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults
South Korea24 participantsStarted 2026-05
Plain-language summary
A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults
Who can participate
Age range
19 Years – 64 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
* Subjects aged 19 years or older and under 65 years at the screening visit
Exclusion Criteria:
* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
* Other exclusions applied
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since AD-230 is only in Phase 1 and is testing how the drug behaves in the body rather than whether it treats chronic liver disease, what does that mean for my chances of getting any direct therapeutic benefit if I were ever considered for this kind of research?
2This trial is listed as 'not yet recruiting' — given where I am in my diagnosis and treatment right now, is it worth waiting to see if this trial opens, or should we be focusing on established treatment options for my chronic liver disease in the meantime?
3The trial is measuring how the drug is absorbed and processed in the bloodstream, including how food affects it — does that tell us anything useful about whether AD-230 might eventually be appropriate for someone with my specific stage or type of chronic liver disease?
4Since Phase 1 trials primarily focus on safety and pharmacokinetics rather than effectiveness, what kinds of safety monitoring or risks should I be aware of before considering any early-phase liver disease drug study like this one?
5Are there currently approved treatments or other clinical trials that are further along in development for chronic liver disease that might be a better fit for me right now, while AD-230 is still in very early testing?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Area under the plasma concentration-time curve during dosing interval (AUCt)